B+
Bull case
30%
Probability
Target price
$18.00
+65.4% vs current
ZVRA
Zevra TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$13.00
+19.5% vs current
B-
Bear case
25%
Probability
Target price
$7.50
-31.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+69.8
Score
AI commentary
Near-term tone improved after the May 6, 2026 earnings release because checked coverage highlighted a revenue and adjusted EPS beat, but the reaction still looks like an early monitoring setup rather than a fully re-rated thesis. Checked analyst pages showed no new post-print target revisions or rating changes through May 7, 2026, which lowers confidence despite the stronger earnings package. Headline volume is moderate, and there was no usable social coverage packet to strengthen conviction.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-09catalystPost-earnings digestion centers on revenue beat and cleaner balance sheetHigh impact
Q1 2026 net revenue rose to $36.2 million from $20.4 million, including $24.6 million of MIPLYFFA revenue, while Zevra reported $236.8 million of cash/investments and had repaid its credit agreement in full on March 12, 2026; the immediate debate is how much of the print was durable commercial progress versus one-time SDX sale benefit [#8-K-2026-05-06] [#10-Q-2026-05-06].
2026-09-30eventFDA follow-up on celiprolol development path in H2 2026High impact
Management said it expects a follow-up FDA meeting in the second half of 2026 to explore pathways to accelerate clinical development for celiprolol after DiSCOVER reached 62 enrolled patients and two confirmed events as of March 31, 2026 [#8-K-2026-05-06] [#10-Q-2026-05-06].
2026-12-31catalystMIPLYFFA commercialization and EMA review remain the core forward value driversHigh impact
The core medium-term setup is continued conversion of MIPLYFFA enrollments and persistence of reimbursement, alongside EMA review of the arimoclomol MAA for NPC; enrollments reached 170 by March 31, 2026 and market access was described as stable at 69% of covered lives [#8-K-2026-05-06] [#10-Q-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology